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“High-risk” human papillomaviruses (HPV) infect keratinocytes of squamous epithelia.
The HPV16E7 protein induces epithelial hyperplasia by binding Rb family proteins and
disrupting cell cycle termination. Murine skin expressing HPV16E7 as a transgene from a
keratin 14 promoter (K14.E7) demonstrates epithelial hyperplasia, dysfunctional antigen
presenting cells, ineffective antigen presentation by keratinocytes, and production of
immunoregulatory cytokines. Furthermore, grafted K14.E7 skin is not rejected from
immunocompetent non-transgenic recipient animals. To establish the contributions of
E7, of E7-Rb interaction and of epithelial hyperplasia to altered local skin immunity,
K14.E7 skin was compared with skin from K14.E7 mice heterozygous for a mutant Rb
unable to bind E7 (K14.E7xRb1L/1L mice), that have normoplastic epithelium. Previously,
we demonstrated that E7-speicfic T cells do not accumulate in K14.E7xRb1L/1L skin
grafts. Here, we further show that K14.E7xRb1L/1L skin, like K14.E7 skin, is not
rejected by immunocompetent non-transgenic animals. There were fewer CD11b+
antigen presenting cells in skin draining lymph nodes from animals recipient of
K14.E7xRb1L/1L grafts, when compared with animals receiving K14.E7 grafts or
K5mOVA grafts. Maturation of migratory DCs derived from K14.E7xRb1L/1L grafts found
in the draining lymph nodes is significantly lower than that of K14.E7 grafts. Surprisingly,
K14.E7xRb1L/1L keratinocytes, unlike K14.E7 keratinocytes, are susceptible to E7
directed CTL-mediated lysis in vitro. We conclude that E7-Rb interaction and its
associated epithelial hyperplasia partially contribute to the suppressive local immune
responses in area affected by HPV16E7 expression.
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INTRODUCTION
Infection of the cervix with high-risk Human Papilloma Virus (HPV) accounts for ∼100% of
cervical cancer. While most high-risk HPV infections can be cleared spontaneously in immune
competent individuals, 1–2% of the infected subjects can progress to cervical intraepithelial
neoplasia (CIN), which can persist for decades before developing into cervical cancer (1). A
major association between development of cervical premalignancy and specific immune response
gene polymorphisms (2) suggests that an inadequate immune response promotes development of
premalignancy, but the basis of this inadequate immune response remains uncertain.
HPV specifically infects basal layer keratinocytes, and the virus life cycle is linked to keratinocyte
differentiation (3).Normally, keratinocytes present antigen to primed T cells (4–6) However,
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HPV16 E7 transgenic primary keratinocytes are not susceptible
to CTL-mediated lysis by E7-specific T cells in vitro (7). This
defect of endogenous antigen presentation could be specific to
the E7 antigen, as keratinocytes expressing OVA as transgene
are sensitive to cell-mediated lysis by CD8+ OT-1 cells (5, 6).
In addition to in vitro studies using immortalized or primary
keratinocytes, a transgenic mouse model expressing HPV16E7
protein controlled by a keratin 14 (K14) promoter (K14.E7)
has been used to study persisting HPV16E7 gene expression, as
this model harbors the molecular features of CIN3 tissue (8).
Multiple local factors including suppressive immunity, mediated
by CD4+CD25+ cells against multiple immunogens (9), IFNγ-
producing NKT cells (10), impaired antigen processing and T cell
activation by antigen-presenting cells (APCs) (11) are observed
in the skin of K14.E7 transgenic mice, and the ear skin of K14.E7
mice is not rejected when grafted to immunocompetent recipient
mice (12), reflecting the failure of clearance of chronic HPV16
infection in some infected humans.
HPV16 E7 protein interacts with multiple proteins including
γ-tubulin, p-600, Retinoblastoma (Rb) protein family, HDAC,
E2F6, p21, and IRF1 (13). The interaction between E7 and
Rb disrupts normal cell cycle regulation, leading to epithelial
hyperproliferation, one of the major pathological phenotypes
of patients with HPV associated CIN3. However, it is unclear
whether suppressed local immunity is a result of E7-associated
hyperplasia or some other consequence of expression of the viral
protein. To dissect this question, we utilized transgenic mice
expressing the E7 protein and with a mutant Rb that is functional
for cell cycle regulation but cannot bind E7 (K14.E7xRb1L/1L)
(14). While expressing a comparable level of E7 transcript,
the skin of K14.E7xRb1L/1L mice, whether homozygous or
heterozygous for the Rb mutation, was found to closely resemble
non-transgenic mouse skin (15, 16). To test whether the local
immune suppression observed in K14.E7 transgenic mouse skin
was due to hyperproliferation or to some other action of E7
protein, we examined immune function in the skin of K14.E7 and
K14.E7xRb1L/1L mice. However, K14.E7xRb1L/1L skin grafts
were not rejected from naïve or E7 primed recipients, and
this was associated with reduced frequency of CD11b+ DC, as
well as the low expression of maturation markers- CD80 and
CD86 on migratory DC subtypes in the skin draining lymph
nodes. More importantly, adaptive immune responses to skin-
directed antigen in K14.E7xRb1L/1L mice were comparable to
those in non-transgenic wild-type mice, and K14.E7xRb1L/1L
transgenic keratinocytes could present endogenous E7-antigen
and be recognized by antigen specific CD8T cells in vitro, unlike
E7 transgenic keratinocytes.
RESULTS
Disruption of E7-Rb Interaction in E7
Transgenic Mice Restores the Peripheral
CD8T Cell Response to That of
Non-transgenic Animals
Mice expressing E7 as a transgene in epithelial cells have altered
immune function locally in skin. The major effects of E7 in
epithelial cells are mediated via binding to the Rb cell cycle
regulatory protein. To determine whether disruption of E7-
Rb interaction impacts on the altered immune response in
E7 transgenic skin, we first examined induction of peripheral
CD8T cell responses, as these are impaired in E7 transgenic
animals to multiple immunogens (9). K14.E7 mice and K14.E7
x Rb1L/1L mice were immunized with ovalbumin (OVA) and
QuilA as adjuvant intradermally, and IFNγ production by CD8T
cells from the draining lymph node in response to SIINFEKL
was measured 6 days after immunization. Re-stimulation with
SIINFEKL resulted in similar numbers of IFNγ producing CD8T
cells for immunized K14.E7xRb1L/1L and Rb1L/1L animals
(Figure 1), while K14E7 animals similarly immunized showed
significantly lower numbers of IFNγ producing CD8T cells than
C57 animals, as previously demonstrated. Thus, expression of
E7 in skin without hyperproliferation does not seem to impair
adaptive immune priming.
K14.E7xRb1L/1L Skin Is Not Rejected From
Immunocompetent Syngeneic Recipients
K14.E7xRb1L/1L mice and non-transgenic mice have similar
skin-infiltrating lymphocytes (16), and exhibit similar CD8T
cell responses to immunization (Figure 1), as well as a similar
transcriptomic profile to non-transgenic mouse skin (16, 17).
We therefore hypothesized that E7-expressing skin lacking
hyperplasia might be susceptible to immune mediated rejection.
To test this, we grafted K14.E7xRb1L/1L skin onto syngeneic
non-transgenic mice. As controls, we grafted hyperplastic NKT
cell deficient Jα18KO× E7 skin, which is susceptible to rejection,
(10) and K14.E7 skin, which is not rejected. iNKT deficient E7
skin grafts (Jα18KO × E7) showed rejection, defined as more
than 50% shrinkage within 42 days (Figures 2A,B). However,
both K14.E7xRb1L/1L and Rb1L/1L skin grafts showed no
evidence of rejection (Figures 2A,B).
As there is no chemokine mediated accumulation of
regulatory T cells in K14.E7xRb1L/1L skin, as observed in
K14.E7 skin, a different mechanism must prevent E7 specific
priming or effector functions where E7 transgenic grafts are
not associated with hyperplasia. Passive transfer of sufficient
E7-specific cytotoxic CD8T cells enabled rejection of E7-
expressing skin grafts following immunization (12).We therefore
tested whether a similar approach would lead to rejection
of K14.E7xRb1L/1L skin grafts. The frequency of various
APC subtypes in skin, lymph nodes and spleen between
E7TCR269 and C57BL/6 did not show significant differences
despite increased frequency of T cells expressing Vβ12 receptor
in E7TCR269 animals (Supplementary Figure 1). K14.E7 and
K14.E7xRb1L/1L skin together were grafted on to the same
E7TCR269 recipient that have an expanded E7-specific CD8T
cell repertoire (9) (Supplementary Figure 1), and to non-
transgenic recipients, with prior immunization with an H-2 Db
restricted peptide of E7 (GF001) (Figure 2C). Consistent with
our previous findings, K14.E7 grafts showed ∼40% reduction
in size on immunized E7TCR269 recipients (Figures 2D,E). In
contrast, K14.E7xRb1L/1L grafts showed no reduction in size
on either C57BL/6 or E7TCR269 recipient mice. These data
demonstrate that failure of E7 transgenic skin grafts to prime
an E7-specific response is not the sole reason for failure of
rejection of K14.E7xRb1L/1L grafts. As E7-expression levels
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FIGURE 1 | K14.E7xRb 1L/1L and non-transgenic mice respond equally to intradermal immunization. OVA specific CD8T cell responses in the draining LN following
intradermal immunization were assessed as IFNγ production following in vitro peptide re-stimulation. (A) Representative FACS plots pre-gated on TCRβ+ CD8T cells
showing IFNγ production with (+) or without (-) SIINFEKL re-stimulation. (B) Quantitative result showing mean ± SEM with n > 3 for each mouse type. Open circle,
without stimulation; closed circle, with stimulation. Analyses were done using one-way ANOVA, with Bonferroni’s multiple comparison tests. Result significance was
shown, where *p < 0.05, ***p < 0.001, and ****p < 0.0001.
are similar in K14.E7 and K14.E7xRb1L/1L skin (16), it is
unlikely that the expression level of the antigen influenced the
fate of K14.E7xRb1L/1L skin grafts. Thus, we hypothesized
three possibilities of why the K14.E7xRb1L/1L skin grafts
are tolerated- (i) K14.E7xRb1L/1L skin graft alone may not
initiate sufficient skin antigen presenting cell migration and
activation in the draining lymph nodes to prime T cells;
(ii) K14.E7xRb1L/1L skin grafts fail to attract effector cells,
consistent with their lower expression of T cell attracting
chemokines (16); (iii) E7 transgenic KC fail to present
antigen effectively in the absence of the local inflammatory
signals (IL-1β, IL-17) that are a feature of K14.E7 skin
(8).
Limited Presence of Graft-Derived
Dendritic Cells in the Draining Lymph Node
Was Observed Upon K14.E7xRb1L/1L
Skin Grafting
To further investigate the induction and attraction of effector
T cells to K14.E7xRb1L/1L skin grafts, we firstly determined
whether K14.E7xRb1L/1L skin-derived dendritic cells, that
might present antigen to activate effector T cells and induce
local chemo attraction and inflammation, could be found in
the graft draining lymph node. K14.E7xRb1L/1L skin was
transplanted onto congenic (CD45.1) recipients and draining
lymph nodes (axillary and inguinal) from both grafted and
non-grafted flanks were harvested 11 days post grafting, after
resolution of any grafting induced inflammation. When K14.E7
skin was similarly transplanted, the frequency of graft derived
APC in the skin graft dropped significantly 7–10 days post
grafting and remained low till day 14. Thus, 10–14 days post
grafting was expected to be when graft-derived DC would be
found in the draining lymph node (Supplementary Figure 2A).
To determine appropriate gating for separation of CD45.1
from CD45.2 lymphocytes, naïve lymph nodes from C57BL/6,
B6.SJL.Ptprca, and 1:1 mixture of the two were stained with
CD45.1 antibody (Supplementary Figure 2B). C57BL/6 skin
grafts were used to control for effects of grafting, Rb1L/1L
grafts were used as control for effects of Rb mutation and
K5mOVA transgenic skin grafts, which are effectively rejected
(18, 19) (Figure 3A) provided a positive control. Graft recipient
CD11c+ cells were similar in number in the draining lymph
node, and in the contralateral node, regardless of graft type
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FIGURE 2 | K14.E7xRb1L/1L skin grafts are not rejected from immunocompetent syngeneic recipients. (A) Grafts of donor ear skin, as shown, onto C57BL/6
recipients at 21 and 42-days post grafting. (B) Area remaining of graft at the indicated time points (DPG). (C) C57BL/6 and E7TCR269 recipients were immunized with
GF001 (50 µg) and QuilA (5µg) subcutaneously 7 days before grafting. (D) Representative photos of graft-bearing recipients on day 21 and day 63. K14.E7 skin (left)
and K14.E7xRb1L/1L skin (right). (E) Area remaining of graft at the indicated time points, compared to the graft on day 21. DPG, day post grafting. Analyses were
done using one-way ANOVA, with Bonferroni’s multiple comparison tests. Error bars showing mean ± SEM with n≥3. Result significance was shown, where
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
(Supplementary Figures 3A,B). Higher number of graft-derived
CD11c+ cells were found in the graft draining lymph node
than in the contralateral node (Supplementary Figure 3C).
However, less graft-derived (CD45.1−) CD11c+ cells were found
in graft draining lymph nodes of animals receiving C57BL/6,
K14.E7xRb1L/1L, or Rb1L/1L grafts when compared with
K5mOVA or K14.E7 skin grafts (Supplementary Figures 3C,D).
Graft-derived cells in the draining nodes (CD45.1−) were further
analyzed based on CD11c and MHCII expression level, to
differentiate migratory DC (CD11c+ MCHIIhi migDC) from
resident DC (CD11c+ MCHIIint ResDC). A significant number
of MigDC, but not ResDC, was found in the draining lymph
nodes (Figure 3B), confirming that the majority of donor
derived lymph node cells were of graft origin. The frequency
of migratory DC (CD11c+ MCHIIhi) in the lymph nodes
of animals receiving K14.E7 grafts was similar to those in
K5mOVA skin graft recipients (Figure 3C). Frequencies of
MigDC in the draining lymph nodes of animals receiving
K14.E7xRb1L/1L skin grafts were however significantly lower
than for K5mOVA grafts and K14.E7 grafts (Figure 3C).
Examining the different DC subtypes, the number of graft-
derived CD11b+ DC per 100,000 live cells in lymph nodes,
but not CD103+ DC or LC, was significantly different amongst
groups receiving different skin grafts (Figure 3D). Thus, these
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FIGURE 3 | The presence of K14.E7xRb1L/1L and K14.E7 DCs from grafted skin in the draining lymph node. Skin-derived DC in graft draining and control lymph
node of CD45.1 recipients receiving K5mOVA, C57BL/6, K14.E7, K14.E7xRb1L/1L, or Rb1L/1L (CD45.2) skin grafts. (A) experimental outline. Draining lymph nodes
(axillary and iguanual) were harvested 11 days after grafting from either grafted side or non-grafted side of one graft recipient. (B) representative plots showing
graft-derived (CD45.1–) DC under live CD45.1–gate. (C) quantitative result of migratory DC [vertical oblong gate in (B)] in grafted draining lymph node of recipients
receiving indicated type of skin grafts. Plot showing the number of cells per 100,000 live cell analyzed. (D) number of cells per 100,000 live cells analyzed of
graft-derived MigDC subtypes (CD103+, CD11b+ and LC) from lymph nodes of mice receiving indicated skin grafts. (E) MFI (top) and percentage (bottom) of CD80
and CD86 positive cells of various DC subtypes in grafted-drianing lymph nodes receiving either K14.E7 (closed circle) or K14.E7xRb1L/1L (opened circle) skin graft.
All statistics were done with one-way ANOVA with Bonferroni post-test. Plots show mean value with SEM. Result significance was shown, where *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
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data confirm that there are more K5mOVA and K14.E7-
derived CD11b+ DC than K14.E7xRb1L/1L and Rb1L/1L-
derived DC.
Next, we further examined the maturation state of different
subtypes of DC in the draining lymph nodes derived from either
K14.E7 or K14.E7xRb1L/1L skin, based on the expression of
CD80 and CD86. Analyzed at the same time point, the percentage
and MFI of CD80 and CD86 on migratory DC, including
CD103+ and CD11b+ migratory DC, are significantly higher
on cells derived from the K14.E7 skin graft (Figure 3E). No
significant difference was observed in resident DC subtypes. This
suggests that K14.E7xRb1L/1L skin graft-derived DC not only
cannot sufficiently migrate to the draining lymph node, but also
that the migrated DC are not mature DC. Together, these results
show that less antigen presenting cells migrate from grafted
K14.E7xRb1L/1L skin than fromK14.E7 skin, which is consistent
with failure of effective presentation of graft derived antigen, and
absence of local induction of T cell derived pro-inflammatory
cytokines.
Keratinocytes With Disrupted E7-Rb
Interaction Engage With Antigen-Specific
CD8T Cells and Enable CTL-Mediated
Lysis
Previously, we have demonstrated that activated antigen-
specific CD8T cells can enter both hyperplastic (K14.E7) and
normoplastic (K14.E7xRb1L/1L) E7-expressing epidermis but
only a very low number of antigen-specific T cells are retained
in the K14.E7xRb1L/1L epidermis (20). Graft rejection requires
effector T cells to engage antigen expressing keratinocytes.
To test whether K14.E7 and K14.E7xRb1L/1L keratinocytes
are equally effective at presenting endogenous E7 antigenic
peptides to effector T cells, flow cytometry sorted keratinocytes
were exposed to HPV16E7-peptide (GF001) (Figure 4A), OVA
(SIINFEKL) (Figure 4B) or not exposed (Figure 4C), and were
co-cultured with E7 peptide-specific effector T cells, or with
SIINFEKL-specific OT-1 cells (Supplementary Figures 5A–C) as
controls. Consistent with our previous findings, keratinocytes
from K14.E7 epithelium were susceptible to CTL-mediated lysis
only when provided with exogenous E7 peptide antigen (6)
(Figure 4A). In contrast, keratinocytes of the K14.E7xRb1L/1L
skin were susceptible to lysis by E7 peptide specific T
cells without exogenous peptide provision (Figure 4C). These
results demonstrate that E7-Rb interaction or E7-induced cell
proliferation interferes with effective MHC class I antigen
presentation, and that disruption of E7-Rb interaction or of the
resulting cellular proliferation can restore the susceptibility of
E7-expressing keratinocytes to cytotoxic T cell killing. Failure of
rejection of K14.E7xRb1L/1L skin must therefore reflect failure
of retention and activation of skin effector T cells in the E7
transgenic skin, perhaps a consequence of failure of local T helper
cell activation.
DISCUSSION
In this study, we modeled the induced immune response
to a tumor antigen expressed in premalignant epithelial
cells, using HPV16 E7 protein transgenic animals. We have
previously shown that immune responses are impaired
following intradermal immunization in HPV16E7-expressing
hyperproliferative epithelium (21). Here, we show that this
impairment is at least in part a consequence of the skin epithelial
hyperplasia associated with E7-Rb interaction, as effective
CD8T cell responses could be produced by intradermal OVA
immunization in K14.E7xRb1L/1L mice lacking epithelial
hyperproliferation.
HPV16E7 transgenic skin models cervical intraepithelial
neoplasia at a transcriptional level (8), and is associated
with suppressed local immunity, as extensively studied
by our laboratory and others (10–12, 15, 22, 23). Local
immunoregulatory mechanisms associated with E7-expressing
hyperproliferative skin have been shown previously to inhibit
rejection of K14.E7 skin grafts. One of the mechanisms
contributing to the suppressive immunity is altered cytokine and
chemokine production favoring a regulatory/inhibitory response
in hyperproliferative epithelium (16). Paradoxically, given
the impaired immune response associated with intradermal
immunization of K14.E7 transgenic animals, we observed in
the current study that grafts of hyperproliferative E7 transgenic
skin placed on immunocompetent animals primed to E7 were
more effectively rejected than grafts of normally proliferating
K14.E7xRb1L/1L skin. This disparity may however in part reflect
the altered immune repertoire associated with E7 expression
and epithelial proliferation in the developing thymus of the
K14.E7 transgenic animal (24) as well as the higher number of
lymphocyte recruitment by the hyperproliferative graft (20).
It is worth noting that in the previous report (20), effector T
cell recruitment to K14.E7 and K14.E7xRb1L/1L skin graft was
assessed 3 days post grafting and showed the lack of effector
T cell recruitment in K14.E7xRb1L/1L skin but not in K14.E7
skin. In this manuscript, we further assessed the outcome of
the skin grafts and agreed with previous finding, in which the
lack of effector T cell recruitment can be one of the causes of
graft tolerance. In studies conducted by Broom et al. (25) and
Hadis et al. (19) in our lab, grafts of skin from mice expressing
OVA from a keratin 5 promoter are rejected when transplanted.
In a study using K14 ovalbumin transgenic mice, the authors
observed no significant inflammatory reaction after adoptive
transfer of activated OVA specific OT-1 cells (26, 27). However,
in studies conducted by Shibaki et al. inflammatory reaction
could be triggered by transferring OT-1 cells without further
activation (28). In each of these studies, the observations were
made on transgenic animals, rather than on grafted transgenic
skin as in our OVA studies.
Rejection of an antigen-expressing skin transplant is typically
initiated by migration of graft-derived DC to the draining lymph
node, where they activate host T cells (29, 30). In addition,
antigen processing and presentation by the recipient’s antigen
presenting cells results in an influx of recipient CD4, CD8T
cells, and CD11b+ macrophages to the graft and graft rejection
(31). Rejection requires presentation of antigen to the recruited
recipient effector cells to elicit antigen specific cytotoxic effect
(32, 33). The hypothesis relates to the migration of potentially
regulatory APC from K14.E7x Rb1L/1L grafts, when compared
with K14.E7 grafts which promote APC migration and suppress
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FIGURE 4 | Keratinocytes from K14.E7xRb 1L/1L skin present endogenous antigen and are susceptible to CTL-mediated lysis. Keratinocytes isolated from the
epidermis of C57BL/6, K14.E7, K14.E7xRb1L/1L, and Rb1L/1L mice were pulsed with (A) GF001 peptide (B) SIINFEKL peptide or (C) without peptide (-) and
co-cultured with E7-specific effector T cells (E7TCR269) at the shown effector/target (E/T) ratios. Keratinocyte death was assessed as LDH release above background
from no-peptide pulsed KC and effector T cell alone. Two independent experiments were done. Target cell maximum release and spontaneous release of LDH are
plotted in Supplementary Figure 4. Data analyzed using two-way ANOVA and applied with Bonferroni post-test. Error bars showing mean ± SEM with 3 to 5
biological replicates in each experimental group. Result significance was shown, where ****p < 0.0001.
systemic E7 immune responses (11). Such migration is not
seen with C57 grafts, or with the appropriate negative control
(Rb1L/1L). In our model, graft-derived APC migration to the
draining lymph node was less with K14.E7xRb1L/1L grafts
than with K14.E7 grafts, and this was not simply due to the
thickness of skin graft, as frequency of APC migrating from
K5mOVA skin grafts, which is known to be rejected upon
transplantation, of similar thickness was also greater. We note
that at the time point of observation, the skin-derived DC
in the draining lymph node may include cells that directly
migrated from the graft and also the cells that proliferated
after migration. Furthermore, the lower frequency of migratory
CD11b+ DC derived from K14.E7xRb1L/1L skin was not
due to the thickness of skin graft, as both K5mOVA and
K14.E7xRb1L/1L skin are normoplastic, having similar numbers
of total live CD45− cells, and similar frequency of various APC
subtypes in the skin (Supplementary Figures 3E,F). Increased
migration might reflect the more inflammatory environment
in hyperproliferative K14.E7 skin, that would enhance antigen
processing and presentation of endogenous antigen by KC (34).
More effective lymphocyte recruitment by the hyperproliferative
K14.E7 than by the normal proliferative K14.E7 graft (20) might
also facilitate graft rejection, and impaired recruitment is a
consequence of lesser production of chemokines (16).
Noting that few effector T cells are recruited to
K14.E7xRb1L/1L skin, we hypothesized that if sufficient
antigen-specific effector T cells were present, antigen-bearing
keratinocytes from the K14.E7xRb1L/1L skin would be
susceptible to T cell mediated killing, and tested this in vitro.
We observed that K14.E7 keratinocytes were susceptible to lysis
only if exogenous peptide was provided, but keratinocytes from
K14.E7xRb1L/1L animals were also able to present endogenous
antigen resulting in lysis. This was not due to differences in
transcription of E7 protein between the two cell populations
(16). Keratinocytes from hyperproliferative epithelium thus
appear to be less effective in vitro at processing or presentation
of endogenous E7 antigen for presentation by MHC Class I.
Their better rejection in vivomight thus reflect better MHC class
I presentation of antigen by keratinocytes in an inflammatory
environment. Determining whether helper T cell mediated
enhancement of E7 presentation enhances E7 graft rejection is
the focus of ongoing studies.
Recently, a small thiadiazolidinedione molecule binding to
pRb through the L × C × E motif has been identified which
selectively interferes with HPV16E7-Rb but not HPV18E7-
Rb interaction (35). This small molecule interrupts the E7-Rb
interaction in the same manner as K14.E7xRb1L/1L. Moreover,
this molecule demonstrated effects on cell cycle and reduced TC-
1 tumor volume after treatment in immune incompetent mice.
While drug mediated interruption of E7- Rb interactions might
slow E7 dependent tumor growth and facilitate induction of
effective peripheral immunity to E7, our results suggest that this
alone may not be sufficient to clear E7 infected cells. However, a
combination of a small molecule inhibitor of Rb-E7 interaction,
and more effective antigen presentation through immunization,
might help to eliminate E7 infected tissues.
MATERIALS AND METHODS
Mice
All mice were maintained in Translational Research Institute
(TRI) Biological Research Facility (BRF) under specific pathogen
free conditions. For experimental work, female mice were used
at 8–12 week of age. C57BL/6 and B6.SJL.Ptprca mice were
obtained from Animal Resources Centre (Perth, Australia) and
OT-1 mice were purchased from The Jackson Laboratories (Bar
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Harbor, ME, USA). K14.E7 (36) and K5mOVA (18) mice were
maintained at the TRI-BRF. Heterozygous Rb1L/1L transgenic
andNKT cell deficient Jα18−/− mice (37) were obtained fromDr.
Fred Dick and Mark Smyth (Melbourne, Australia), respectively,
and maintained locally at TRI-BRF. K14.E7xRb1L/1L and
Jα18−/−xE7 mice were generated by mating heterozygous
K14.E7 with heterozygous Rb1L/1L and homozygous Jα18−/−,
respectively. K14.E7xRb1L/1L mice have a single allele of E7
transgene and at least one allele of mutated Rb. OT-I mice
were purchased from The Jackson Laboratories (Bar Harbor, ME,
USA). E7TCR269 mice were bred as previously described (9).
Immunization
Immunizations were performed by injecting 5 µg QuilA (Sigma-
Aldrich, St. Louis, MO, USA) with 50 µg OVA (A5503,
Sigma-Aldrich, St. Louis, MO, USA) or E7 peptide-GF001
(RAHYNIVTF, synthesized by Auspep Pty Ltd, (Melbourne,
Australia), with purity >80%) in 20 µl PBS into one ear pinnae
intradermally or 200 µl PBS subcutaneously.
Isolation of Cells From Lymph Node and
Spleen
The isolation was done as previously described (16). Lymph
nodes were digested with 1 µg/µl, of collagenase D (Roche) and
0.2 µg/µl of DNase, (Roche) for 30min at 37
◦
C prior to passing
through the cell strainer.
FACS, Antibodies and Reagents
FACS analysis was undertaken as previously described (10).
Foxp3 Fix/Perm Concentrate and Diluent kit (eBioscience, San
Diego, USA) was used for intracellular staining of IFNγ. Anti-
mouse monoclonal antibodies to CD45 (30-F11), CD45.1 (A20),
CD8α (53-6.7), TCRβ (H57-597), CD4 (GK1.5), EpCAM (G8.8),
I-A/I-E (MHCII) (M5/114.15.2), CD103 (M290), CD11c (HL3),
CD11b (M1/70), IFNγ (XMG1.2) and the corresponding isotype
antibodies were purchased from Biolegend (San Diego, USA),
eBioscience (San Diego, USA), BD Bioscience (San Jose, USA).
In vitro Cytotoxic T Cell Assay
Effector cells (E) were harvested from the spleen of E7TCR269
and OT-1 mice 6 days after GF001 and OVA immunization,
respectively. Splenocytes were cultured in standard RPMI and
supplemented with IL-2 (1 U/mL, Peprotech, NJ, USA) overnight
and CD8T cells were enriched using biotinylated antibodies (16).
Target keratinocytes (T) were sorted using BD FACSAria Fusion
Sorter and pulsed with 10µg/mL of either GF001 or SIINFEKL
(Sigma-Aldrich, St. Louis, MO, USA) peptide. Effector and target
cells were co-cultured at 20:1, 10:1, or 2.5:1 ratio for 5 h and cell-
mediated cytotoxicity assay was performed using CytoTox 96 R©
Non-Radioactive Cytotoxicity Assay kit (Promega, Madison,
WI, USA) following manufacturer’s instruction. Percentage of
cytotoxicity was calculated as per manufacturer’s instruction
(each value calculated has been subtracted with medium
background):








− (KC spontaneous release)
(KC maximum release)− (KC spontaneous release)
x 100% (1)
Skin Grafting
Skin grafting was performed as previously described (38). Briefly,
skin graft recipients were shaved on the flank and shaved skin
was cut out in the size that matches the donor skin. Ears from the
donor mice were split into dorsal and ventral part and grafted
onto recipient mice. Bactigras (Smith and Nephew, Australia)
was placed, following by bandaging. The bandage was taken off 7
days after the procedure. Day 21 post-grafting was set as baseline
for comparison as the skin grafts are well-healed and no local
inflammation was observed.
Statistical Analysis
Prism 7 (GraphPad Software, La Jolla, CA) software was used
for statistical analysis and to prepare the plots. Unless otherwise
stated, all analyses were done using one-way ANOVA, with
Bonferroni’s multiple comparison tests. Two-way ANOVA with
Bonferroni’s post-test analysis was used in Figure 4. All plots
show mean value with SEM. Paired-student t-test was used
in Figure 3B. Result significance was shown, where ∗p<0.05,
∗∗p<0.01, ∗∗∗p<0.001, and ∗∗∗∗p<0.0001.
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